GIP/GLP1 Agonist Compositions
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 62/688,632, filed Jun 22, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,357,820 | GIP/GLP1 Agonist Compositions In force · High confidence UsedRemaining | Eli Lilly and Company | In force | High confidence | ||
| US 11,918,623 | GIP/GLP1 Agonist Compositions In force · High confidence | Eli Lilly and Company | In force | High confidence | ||
| US 12,453,755 | GIP/GLP1 Agonist Compositions In force · High confidence | Eli Lilly and Company | In force | High confidence | ||
| US 12,453,756 | GIP/GLP1 Agonist Compositions In force · High confidence | Eli Lilly and Company | In force | High confidence | ||
| US 12,629,404 | GIP/GLP1 Agonist Compositions In force · High confidence | Eli Lilly and Company | In force | High confidence | ||
| Application 19/276,978 | GIP/GLP1 Agonist Compositions Pending Not granted | Eli Lilly and Company | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Eli Lilly and Company.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.